Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Advanced Medical Solutions buys Resorba. Roche picks up Verum Diagnostica. Invacare enters discussions for consent decree.

You may also be interested in...



Invacare Compliance Challenges, Product Delays Impact Q3 Results

Talks with FDA are ongoing about compliance with quality system regulations and a proposed consent decree that would shut down certain operations at a wheelchair manufacturing plant in Elyria, Ohio, executives said during the firm’s Oct. 25 earnings call.

Regulatory News In Brief

Fiscal 2012 budget cuts: White House Office of Management and Budget Director Peter Orszag and White House Chief of Staff Rahm Emanuel are directing federal agencies to find ways to cut their fiscal 2012 budgets by 5%, according to a June 8 1memo and budget 2guidance. Agencies should identify programs "that have the lowest impact on your agency's mission," the memo states. Fiscal 2012 budget submissions are due to OMB by Sept. 13. The Obama administration has pledged to freeze non-security discretionary spending through fiscal 2013

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Latest Headlines
See All
UsernamePublicRestriction

Register

MT030805

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel